Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· May 12, 2026

Dollar Rallies on Crude Oil Strength as Hot US CPI Report

View original at nasdaq.com
Dollar Rallies on Crude Oil Strength as Hot US CPI Report The dollar index (DXY00) today is up by +0.45%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Markets are discounting a 77% chance of a 25 bp BOJ rate hike at the next policy meeting on June 16

    60% confidence
  • Swaps are discounting an 86% chance of a +25 bp rate hike by the ECB at the next policy meeting on June 11

    60% confidence
  • It is quite possible that the BOJ will raise the policy interest rate from the next policy meeting onward, even if the future course of the situation in the Middle East remains unclear

    60% confidence
  • Inflation risks are worsening and circumstances point to an ECB interest rate hike in June

    60% confidence
  • The current US-Iran ceasefire is on 'life support'

    60% confidence
  • Japan imports more than 90% of its energy needs, making the yen vulnerable to crude oil price surges

    60% confidence
  • Swaps markets are discounting the odds at 5% for a 25 bp rate cut at the next FOMC meeting on June 16-17

    60% confidence
  • Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article on the date of publication

    60% confidence
  • The worst part of the April CPI report is services inflation and the Fed has to think about how to break the chain of escalating inflation

    60% confidence
  • The US has an inflation problem

    60% confidence
  • Strong central bank demand for gold is supportive of gold prices following PBOC's eighteenth consecutive month of reserve increases

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com